Conjugated estrogens and hypercoagulability.
A group of 11 menopausal women receiving 1.25 mg. of conjugated estrogens daily had coagulation tests to determine the development of hypercoagulability after taking 5 and 21 tablets. There was no essential change in thrombin generation or fibrinolytic activity as measured by euglobin lysis time. There was a shift toward hypercoagulability in all three parameters of the thrombelastograms. The decrease of the antithrombin III activity was not as pronounced following the administration of conjugated estrogens as had been the change associated with oral contraceptives. Fibrin monomers were observed in some women during the first week of Premarin therapy.
D000328:Adult; D000991:Antithrombins / Q000032:analysis; D001777:Blood Coagulation / Q000187:drug effects*; D001780:Blood Coagulation Tests; D003276:Contraceptives, Oral / Q000494:pharmacology*; D003278:Contraceptives, Oral, Hormonal / Q000494:pharmacology*; D004966:Estrogens, Conjugated (USP) / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D005337:Fibrin / Q000032:analysis; D005342:Fibrinolysis; D006801:Humans; D008593:Menopause; D008875:Middle Aged; D013916:Thrombelastography; D013917:Thrombin / Q000032:analysis
D000991:Antithrombins; D003276:Contraceptives, Oral; D003278:Contraceptives, Oral, Hormonal; D004966:Estrogens, Conjugated (USP); D005337:Fibrin; D013917:Thrombin